[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352587-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352587-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","increased-cytoplasmic-and-nuclear-s100a6-expression-is-associated-with-improved-prognosis-in-ovarian-cancer","Increased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer","","Ovarian cancer remains a leading gynecological malignancy worldwide, yet the clinical relevance of S100 calcium-binding protein A6 (S100A6) in this disease is unclear. This study assesses how cytoplasmic versus nuclear S100A6 protein levels relate to survival and clinicopathological features, using immunohistochemistry in 462 tumors and TCGA PanCancer validation in 299 cases. High cytoplasmic and high nuclear expression each correlate with improved overall survival, while mRNA levels show no significant prognostic association.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/increased-cytoplasmic-and-nuclear-s100a6-expression-is-associated-with-improved-prognosis-in-ovarian-cancer/352587/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/increased-cytoplasmic-and-nuclear-s100a6-expression-is-associated-with-improved-prognosis-in-ovarian-cancer/352587.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about S100A6 in ovarian cancer?","Question",{"text":63,"@type":64},"It investigates whether cytoplasmic and nuclear S100A6 expression levels are linked to patient survival and clinicopathological outcomes in ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were S100A6 expression levels measured?",{"text":68,"@type":64},"Cytoplasmic and nuclear S100A6 protein levels were evaluated using immunohistochemistry in 462 ovarian tumors, with additional analysis of S100A6 expression from TCGA PanCancer (n=299).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main prognostic findings?",{"text":72,"@type":64},"High cytoplasmic S100A6 expression and high nuclear S100A6 expression were both significantly associated with better overall survival, whereas mRNA S100A6 levels did not show significant associations with overall survival or progression-free survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352587,1790484901,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Farooq et al. BMC Cancer (2026) 26:368 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15631-0](https://doi.org/10.1186/s12885-026-15631-0)  \nRESEARCH Open Access  \nIncreased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer  \nAruba Farooq1, Evren M. Akyuz 1, Brandon WQ Cheah1, Suha Deen2, Stewart G. Martin3, Mattéa J. Finelli4, Sarah Storr3 and Alan McIntyre1,3*  \nAbstract  \nBackground Ovarian cancer is one of the most common gynaecological cancers affecting more than 300,000 women worldwide each year. S100 calcium-binding protein A6 (S100A6) is a member of the S100 family of calciumbinding proteins. Upon activation by calcium (Ca2+ ) signalling, S100A6 regulates numerous cellular processes including cell proliferation and metastasis. The role of S100A6 is well established across multiple tumour types where increased S100A6 expression contributes to tumourigenesis and worse patient outcome. However, the role of S100A6 in ovarian cancer is not well established.  \nMethods The impact of cytoplasmic and nuclear S100A6 expression on overall survival and clinicopathological criteria was investigated in 462 ovarian tumours by immunohistochemistry. Additionally, S100A6 expression inan ovarian cancer cohort from The Cancer Genome Atlas (TCGA) PanCancer dataset (n = 299) was evaluated and associations with overall survival and progression-free survival were identified.  \nResults Immunohistochemical staining revealed that high cytoplasmic expression of S100A6 was significantly associated with better overall survival (p = 0 . 014) . Additionally, high nuclear expression was significantly associated with better overall survival (p = 0 . 036) . In contrast, analysis of mRNA S100A6 suggests no significant association of mRNA levels for overall survival (p = 0 . 903) and progression free survival (p = 0 . 278) .  \nConclusions Our data provides novel insights regarding the clinical implications of S100A6 expression in ovarian cancer, providing strong rationale for functional investigations of S100A6 in ovarian cancer.  \nKeywords S100A6, Ovarian cancer, Survival  \n*Correspondence:  \nAlan McIntyre  \n[alan.mcintyre@nottingham.ac.uk](alan.mcintyre@nottingham.ac.uk)  \n1Hypoxia and Acidosis Research Group, Centre for Cancer Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK  \n2Department of Pathology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK  \n3Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK 4School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nFarooq et al. BMC Cancer (2026) 26:368  \nIntroduction  \nOvarian cancer  \nCancer remains a global health concern with incidence and mortality increasing [1]. Ovarian cancer is a common gynaecological cancer affecting more than 300,000 women each year worldwide [1, 2]. In the UK, ovarian cancer is the sixth most common","cbCaiiFB7FR4AY02","https://ap.wps.com/l/cbCaiiFB7FR4AY02","pdf",1739537,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Ovarian cancer\n## S100A6","[{\"question\":\"What question does the study address about S100A6 in ovarian cancer?\",\"answer\":\"It investigates whether cytoplasmic and nuclear S100A6 expression levels are linked to patient survival and clinicopathological outcomes in ovarian cancer.\"},{\"question\":\"How were S100A6 expression levels measured?\",\"answer\":\"Cytoplasmic and nuclear S100A6 protein levels were evaluated using immunohistochemistry in 462 ovarian tumors, with additional analysis of S100A6 expression from TCGA PanCancer (n=299).\"},{\"question\":\"What were the main prognostic findings?\",\"answer\":\"High cytoplasmic S100A6 expression and high nuclear S100A6 expression were both significantly associated with better overall survival, whereas mRNA S100A6 levels did not show significant associations with overall survival or progression-free survival.\"}]","Increased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer | PDF",1790100356,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8408e95a119acef2f057879c6be079b.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43b6cecccba9fe2c953c2c064c29cf43.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64477450a258e0e5e6dc0f4972502405.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31cc157c806853919bc099eecca7b5d2.webp",980,1306]